UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 654

Sortiert nach

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

Molecular cancer therapeutics, 2017-11, Vol.16 (11), p.2598-2608

2017

Link zum Volltext

Verfügbarkeit prüfen

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

Molecular cancer therapeutics, 2015-04, Vol.14 (4), p.847-856

2015

Link zum Volltext

Verfügbarkeit prüfen

Impact of Sotorasib and Adagrasib in KRAS G12C--Mutated NSCLC

Oncology (Williston Park, N.Y.), 2023-12, Vol.37 (12), p.479

Patel, Sandip P

2023

Link zum Volltext

Verfügbarkeit prüfen

Probing the Complexities of Astrocyte Calcium Signaling

Trends in cell biology, 2016-04, Vol.26 (4), p.300-312

2016

Link zum Volltext

Verfügbarkeit prüfen

Deep coverage and quantification of the bone proteome provides enhanced opportunities for new discoveries in skeletal biology and disease

PloS one, 2023-10, Vol.18 (10), p.e0292268-e0292268

2023

Link zum Volltext

Verfügbarkeit prüfen

Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients

Clinical cancer research, 2016-11, Vol.22 (22), p.5497-5505

2016

Link zum Volltext

Verfügbarkeit prüfen

Ins and outs of Ca2+ transport by acidic organelles and cell migration

Communicative & integrative biology, 2018-01, Vol.11 (1), p.803-13

Patel, Sandip

2018

Link zum Volltext

Verfügbarkeit prüfen

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

Clinical cancer research, 2020-05, Vol.26 (10), p.2290-2296

2020

Link zum Volltext

Verfügbarkeit prüfen

Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy

Clinical cancer research, 2017-10, Vol.23 (19), p.5729-5736

2017

Link zum Volltext

Verfügbarkeit prüfen

Two-pore channels at the intersection of endolysosomal membrane traffic

Biochemical Society transactions, 2015-06, Vol.43 (3), p.434

2015

Link zum Volltext

Verfügbarkeit prüfen

Function and dysfunction of two-pore channels

Science signaling, 2015-07, Vol.8 (384), p.re7

Patel, Sandip

2015

Link zum Volltext

Verfügbarkeit prüfen

Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma

Clinical cancer research, 2017-09, Vol.23 (17), p.5101-5111

2017

Link zum Volltext

Verfügbarkeit prüfen

Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response

Clinical cancer research, 2020-05, Vol.26 (10), p.2434-2434

2020

Link zum Volltext

Verfügbarkeit prüfen

Rapid Discrimination of Malaria- and Dengue-Infected Patients Sera Using Raman Spectroscopy

Analytical chemistry (Washington), 2019-06, Vol.91 (11), p.7054-7062

2019

Link zum Volltext

Verfügbarkeit prüfen

ALKBH5 regulates anti–PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment

Proceedings of the National Academy of Sciences - PNAS, 2020-08, Vol.117 (33), p.20159-20170

2020

Link zum Volltext

Verfügbarkeit prüfen

Disparities in telemedicine during COVID‐19

Cancer medicine (Malden, MA), 2022-02, Vol.11 (4), p.1192-1201

2022

Link zum Volltext

Verfügbarkeit prüfen

Germline DNA damage response gene mutations as predictive biomarkers of immune checkpoint inhibitor efficacy

Frontiers in immunology, 2024, Vol.15, p.1322187-1322187

2024

Link zum Volltext

Verfügbarkeit prüfen

Mining of Ebola virus entry inhibitors identifies approved drugs as two-pore channel pore blockers

Biochimica et biophysica acta. Molecular cell research, 2019-07, Vol.1866 (7), p.1151-1161

2019

Link zum Volltext

Verfügbarkeit prüfen

Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications

BMC cancer, 2020-05, Vol.20 (1), p.383-13, Article 383

2020

Link zum Volltext

Verfügbarkeit prüfen

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Journal for immunotherapy of cancer, 2021-08, Vol.9 (8), p.e002990

2021

Link zum Volltext

Verfügbarkeit prüfen

Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support

Molecular cancer therapeutics, 2017-12, Vol.16 (12), p.2645-2655

2017

Link zum Volltext

Verfügbarkeit prüfen

First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20 + Non-Hodgkin Lymphomas

Clinical cancer research, 2020-06, Vol.26 (11), p.2524-2534

2020

Link zum Volltext

Verfügbarkeit prüfen

Assessment of Anti-urolithic effect of the Ocimum basilicum L. seed extract on Ethylene Glycolinduced urolithiasis in male rats

Research journal of pharmacy and technology, 2023-07, Vol.16 (7), p.3367-3372

2023

Link zum Volltext

Verfügbarkeit prüfen

In Vitro Cytotoxicity and Aromatase Inhibitory Activity of Flavonoids: Synthesis, Molecular Docking and In silico ADME Prediction

Anti-cancer agents in medicinal chemistry, 2022-04, Vol.22 (7), p.1370

2022

Link zum Volltext

Verfügbarkeit prüfen

SPP1 and UMOD gene variants are synergistically associated with risk of renal stone disease

Gene, 2023-05, Vol.863, p.147264-147264, Article 147264

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 654

Suche als RSS-Feed

Aktive Filter

KollektionJournals@Ovid

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(491)
Mit Volltextzugriff
(577)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(13)

Menü

Weitere Dienste

Einstellungen

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

Impact of Sotorasib and Adagrasib in KRAS G12C--Mutated NSCLC

Probing the Complexities of Astrocyte Calcium Signaling

Deep coverage and quantification of the bone proteome provides enhanced opportunities for new discoveries in skeletal biology and disease

Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients

Ins and outs of Ca2+ transport by acidic organelles and cell migration

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy

Two-pore channels at the intersection of endolysosomal membrane traffic

Function and dysfunction of two-pore channels

Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma

Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response

Rapid Discrimination of Malaria- and Dengue-Infected Patients Sera Using Raman Spectroscopy

ALKBH5 regulates anti–PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment

Disparities in telemedicine during COVID‐19

Germline DNA damage response gene mutations as predictive biomarkers of immune checkpoint inhibitor efficacy

Mining of Ebola virus entry inhibitors identifies approved drugs as two-pore channel pore blockers

Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support

First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20 + Non-Hodgkin Lymphomas

Assessment of Anti-urolithic effect of the Ocimum basilicum L. seed extract on Ethylene Glycolinduced urolithiasis in male rats

In Vitro Cytotoxicity and Aromatase Inhibitory Activity of Flavonoids: Synthesis, Molecular Docking and In silico ADME Prediction

SPP1 and UMOD gene variants are synergistically associated with risk of renal stone disease

Aktive Filter

Suchergebnisse filtern